Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer.
brain
cerebrospinal
depocyte
meningitis
neoplastic
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
15 04 2020
15 04 2020
Historique:
pubmed:
23
10
2019
medline:
28
4
2021
entrez:
23
10
2019
Statut:
ppublish
Résumé
DEPOSEIN (NCT01645839) was a randomized open-label phase III study to explore the role of intrathecal chemotherapy in patients with newly diagnosed leptomeningeal metastasis (LM), a common manifestation of breast cancer. Patients with newly diagnosed LM defined by tumor cells in the cerebrospinal fluid or combination of clinical and neuroimaging signs of LM were randomized to receive systemic therapy alone (control group) or systemic therapy plus intrathecal liposomal cytarabine (experimental group). Progression-free survival related to LM (LM-PFS) was the primary endpoint. Thirty-seven and 36 patients were assigned to the control and the experimental groups. Median number of liposomal cytarabine injections in the experimental group was 5 (range 1-20). Focal radiotherapy was performed in 6 (16%) and 3 (8%) patients in the control and experimental groups. In the intent-to-treat population, median LM-PFS was 2.2 months (95% CI: 1.3-3.1) in the control versus 3.8 months (95% CI: 2.3-6.8) in the experimental group (hazard ratio 0.61, 95% CI: 0.38-0.98) (P = 0.04). Seventy-one patients have died. Median overall survival was 4.0 months (95% CI: 2.2-6.3) in the control versus 7.3 months (95% CI: 3.9-9.6) in the experimental group (hazard ratio 0.85, 95% CI: 0.53-1.36) (P = 0.51). Serious adverse events were reported in 22 and 30 patients, respectively. Quality of life until progression did not differ between groups. The addition of intrathecal liposomal cytarabine to systemic treatment improves LM-related PFS. Confirmatory trials with optimized patient selection criteria and more active drugs may be required to demonstrate a survival benefit from intrathecal pharmacotherapy.
Sections du résumé
BACKGROUND
DEPOSEIN (NCT01645839) was a randomized open-label phase III study to explore the role of intrathecal chemotherapy in patients with newly diagnosed leptomeningeal metastasis (LM), a common manifestation of breast cancer.
METHODS
Patients with newly diagnosed LM defined by tumor cells in the cerebrospinal fluid or combination of clinical and neuroimaging signs of LM were randomized to receive systemic therapy alone (control group) or systemic therapy plus intrathecal liposomal cytarabine (experimental group). Progression-free survival related to LM (LM-PFS) was the primary endpoint.
RESULTS
Thirty-seven and 36 patients were assigned to the control and the experimental groups. Median number of liposomal cytarabine injections in the experimental group was 5 (range 1-20). Focal radiotherapy was performed in 6 (16%) and 3 (8%) patients in the control and experimental groups. In the intent-to-treat population, median LM-PFS was 2.2 months (95% CI: 1.3-3.1) in the control versus 3.8 months (95% CI: 2.3-6.8) in the experimental group (hazard ratio 0.61, 95% CI: 0.38-0.98) (P = 0.04). Seventy-one patients have died. Median overall survival was 4.0 months (95% CI: 2.2-6.3) in the control versus 7.3 months (95% CI: 3.9-9.6) in the experimental group (hazard ratio 0.85, 95% CI: 0.53-1.36) (P = 0.51). Serious adverse events were reported in 22 and 30 patients, respectively. Quality of life until progression did not differ between groups.
CONCLUSION
The addition of intrathecal liposomal cytarabine to systemic treatment improves LM-related PFS. Confirmatory trials with optimized patient selection criteria and more active drugs may be required to demonstrate a survival benefit from intrathecal pharmacotherapy.
Identifiants
pubmed: 31637444
pii: 5602197
doi: 10.1093/neuonc/noz201
pmc: PMC7158648
doi:
Substances chimiques
Cytarabine
04079A1RDZ
Banques de données
ClinicalTrials.gov
['NCT01645839']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
524-538Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Cancer Treat Rev. 1993;19 Suppl A:73-84
pubmed: 7679323
J Neurooncol. 2013 Sep;114(2):229-35
pubmed: 23756727
Breast Cancer Res Treat. 2014 Aug;146(3):477-86
pubmed: 25038877
J Clin Oncol. 1993 Mar;11(3):561-9
pubmed: 8445432
Neuro Oncol. 2014 Sep;16(9):1176-85
pubmed: 24867803
Eur J Cancer. 2004 Dec;40(18):2726-33
pubmed: 15571954
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
J Neurooncol. 2018 May;138(1):191-198
pubmed: 29435818
Neuro Oncol. 2019 May 6;21(5):648-658
pubmed: 30715514
Ann Oncol. 2017 Jul 1;28(suppl_4):iv84-iv99
pubmed: 28881917
J Neurooncol. 2017 Jun;133(2):419-427
pubmed: 28455788
J Neurooncol. 2013 May;113(1):83-92
pubmed: 23456656
Clin Cancer Res. 1999 Nov;5(11):3394-402
pubmed: 10589750
Clin Breast Cancer. 2017 Feb;17(1):23-28
pubmed: 27569275
Eur J Cancer. 2018 May;95:75-84
pubmed: 29635147
Adv Neurol. 1978;19:579-92
pubmed: 570349
J Clin Oncol. 1987 Oct;5(10):1655-62
pubmed: 3309199